Company ProfilePremium

Cosmax BTI, Inc.

Company Profile Analysis

코스맥스비티아이 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cosmax BTI, Inc. - Company showcase

Year Founded & Workforce

1992

341 Employees

Cosmax BTI, Inc. logo

Cosmax BTI, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cosmax BTI, Inc. Overview

Cosmax BTI is the apex holding company of the Cosmax Group, the Korean-founded enterprise widely described as the world's largest cosmetics original design manufacturer (ODM). Its economic value rests on three layers. First, an equity-method stake of roughly 27% in Cosmax, Inc., the group's listed cosmetics ODM, which reported record FY2025 revenue of KRW 2,398.8 bn and operating profit of KRW 195.8 bn. Second, controlling stakes in a health-functional-food (HFF) ODM platform — KOSDAQ-listed Cosmax NBT (43.53%) and unlisted Cosmax Bio (68.37%) — plus a small pharmaceutical subsidiary, Cosmax Pharma (79.64%). Third, its own "separate" operations: global raw-material purchasing and export agency for group companies, shared-services fees, and dividend income. Consolidated FY2025 revenue was KRW 645.2 bn with operating profit of KRW 27.0 bn. The stock trades at a deep discount to the market value of its listed holdings, and family succession was formalised in May 2026.


What the company does

Cosmax BTI performs two functions simultaneously:

  1. Pure holding/control function. It sets group vision and strategy, allocates capital, oversees human-resources and financing plans, and holds controlling or significant stakes in operating companies. The company's own description (group website) characterises BTI as the body that sets strategic goals and develops HR and financing plans for the whole Cosmax Group, while securing growth engines in health and functional foods, bio-capsules and new businesses beyond the cosmetics core.

  2. Operating ("business holding") function. The parent entity itself books revenue from (a) sales of goods and merchandise — principally global raw-material procurement and export agency services for subsidiaries and the Cosmax, Inc. associate; (b) shared-services-center (SSC) fees and service revenue; and (c) dividend income from affiliates. Per a valuation-platform summary of the FY2025 annual report, BTI had 14 consolidated subsidiaries as of June 2025 and performs global raw-material purchasing and export agency for subsidiaries.

Reporting segments (as presented in company IR materials)

SegmentEntityOwnership by BTIAccountingBusiness
Health functional food (NBT)Cosmax NBT, Inc. (KOSDAQ: 222040)43.53% direct (43.93% incl. related parties), FY2025 annual reportConsolidatedHFF ODM/OBM with Korea–Australia–China–US value chain
Health functional food (BIO)Cosmax Bio, Inc. (unlisted)68.37% (FY2025 annual report)ConsolidatedHFF ODM — tablets, softgels, liquids, jellies, powders
PharmaCosmax Pharma, Inc. (unlisted)79.64% (FY2025 annual report)ConsolidatedPharmaceutical intermediates and finished drugs (CMO-type)
Holding (BTI separate)Cosmax BTI parent—ParentRaw-material sourcing/export agency, SSC fees, dividends
Cosmetics ODM (associate)Cosmax, Inc. (KOSPI: 192820)27.23% direct; 27.51% incl. related parties (FY2025 annual report)Equity methodWorld's largest cosmetics ODM

Revenue model

Product (ODM/OEM manufacturing): the overwhelming majority of consolidated revenue — contract development and manufacturing of HFF and pharmaceuticals for brand owners (NBT, Bio, Pharma).

Trading/merchandise: BTI-separate procurement and resale of raw materials/merchandise to affiliates.

Services/fees: SSC and management-service fees.

Investment income: dividends (booked as revenue in BTI-separate; e.g., KRW 10.1 bn of FY2025 dividends recognised in Q1 2026) and equity-method income from Cosmax, Inc. (non-operating, below operating profit).

Subscription/licensing: not material / not disclosed.

Revenue mix by business (Q2 2026, per Butler/DART summary): health functional foods 64%, other (holding/trading) 32%, pharma 4%.

Value-chain position, customers and end-markets

The group sits in the B2B "invisible" middle of the beauty and wellness value chain — between ingredient suppliers and consumer brands. Customers are brand owners: global multinationals (Fortune's 2026 profile cites Shiseido, Yves Saint Laurent and Lancôme among Cosmax's roughly 4,500–5,000 customers), Korean "indie" K-beauty brands, Chinese domestic brands (e.g., Yatsen via JV), and, in HFF, network-marketing (MLM) companies, large retailers, home shopping, online channels, and pharma companies.

End-markets: skincare, color cosmetics, suncare, hair/body (via Cosmax, Inc.); dietary supplements/HFF (vitamins, probiotics, collagen, individually-recognised functional ingredients); and generic/OTC pharmaceutical products (Cosmax Pharma).

Independent characterisation

Economically, Cosmax BTI is best understood as a leveraged, owner-controlled holding vehicle whose net asset value is dominated by its Cosmax, Inc. stake, wrapped around a sub-scale and historically loss-making HFF manufacturing platform. Consolidated earnings understate BTI's look-through earnings power because Cosmax, Inc.'s profits arrive only as equity-method income and dividends. The investment case therefore hinges on (i) Cosmax, Inc.'s K-beauty-driven growth, (ii) whether the HFF turnaround visible in H1 2026 is durable, and (iii) whether governance and capital-allocation changes narrow the holding-company discount.

Strategy

Stated strategic themes

Holding-company role: set group vision/strategy; build HR and financing plans; secure growth engines in HFF, bio-capsules and new businesses beyond cosmetics.

Two-track growth (beauty + HFF): the group's long-standing "two-track" strategy; the HFF leg has underperformed (group HFF revenue ~KRW 460 bn in 2021 vs ~KRW 450 bn in 2025, per BizWatch).

Group revenue ambition: KRW 3 trillion group revenue target (recruitment-platform summary of company materials).

Customer diversification: reduce reliance on large clients; attract indie brands via lower minimum order quantities and smart-factory, high-mix/low-volume production.

Global production efficiency: Ohio exit, US integration, California sales expansion; NBT shift to sales-led US model.

Shareholder returns: dividend policy disclosure since 2023 to improve predictability; FY2025 payout 25.5%.

Initiatives in the last 24 months

InitiativeDateDescription / target
Professional co-CEO modelMar 2025 – Sep 2026Huh Min-ho tasked with holding-company system, mid/long-term strategy, management infrastructure, B2C/new business — ended with resignation
NBT US restructuring2025–2026Production ended; plant sold in two stages; proceeds earmarked for debt repayment
Cosmax Bio JellixNov 2024 onwardJelly-format capacity for domestic and export demand
K-health export support2025–2026NBT/Bio supporting Korean brands' exports; NBT USD 70 m and Bio USD 5 m export towers (Dec 2025)
Keminova acquisition (associate level)Feb–Apr 2026First European base; post-merger integration, joint R&D, planned "Keminova Academy"
L'Oréal MOU (associate level)Sep 2026Joint K-beauty-inspired global product development, ingredients, sensory formats
Value-up plan (Cosmax, Inc.)Nov 2025Corporate value-enhancement plan; dividend predictability; governance improvement; annual ESG reports
High-dividend company statusMar 2026Both BTI and Cosmax, Inc. qualified, enabling separate taxation of dividends for shareholders
Custom-cosmetics platform 3WAAUOngoingOne-to-one personalised production, B2C pilot
GrowX2026 (reported)Marketing-consulting subsidiary for cosmetics/HFF

Management targets / guidance

Cosmax BTI: no formal consolidated numeric guidance identified. Q4 2025 commentary: continued domestic HFF growth and export support with client-portfolio diversification; pharma to diversify customers and launch new products.

Cosmax, Inc. (associate) 2025 guidance (given Feb 2025): Korea revenue +20%, sun care +50%+, Korea OPM 10%; China East +10%; Indonesia +25%; Thailand +50%; US +10%+ and H2 breakeven. Outcome: Korea grew 12.4%; US breakeven slipped to Q2 2026.

Cosmax, Inc. Q2 2026 guidance (given May 2026): Korea mid-teens growth, China ~20%, US 30%+, Indonesia ~20%. Outcome: Korea +23%, China +33%, US +79%, Indonesia +38% — beat.

Cosmax Bio: 2021 target of KRW 500 bn revenue by 2026 — effectively abandoned (FY2025: KRW 168.2 bn).

Products & Services

Cosmax BTI does not sell branded consumer products at scale; its "products" are manufacturing and development capabilities offered to brand owners. Catalog by business:

Cosmax NBT (HFF ODM/OBM)

OfferingDescription / capabilityTarget customerNotes
Custom HFF formulation & manufacturingMulti-format supplements (tablets, capsules, powders etc.) across Korea, Australia, China; US now sales-ledMLM firms, retailers, global brands, China-bound brandsOverseas share >70% of revenue (2025)
Individually-recognised functional ingredients9 MFDS-approved proprietary ingredients incl. wheat-germ-oil extractBrands seeking differentiated claimsPer FY2025 annual-report summary
Women's vaginal-health probiotic "Respecta"Proprietary individually-recognised probiotic ingredientWomen's-health brandsQuarterly sales ~KRW 6 bn in Q1 2021 (IBK)
Australia premium export productionPlant oriented to premium products for China-bound clientsGlobal/China brandsPlant completed 2017
Big-data prescription automation; micro-size formatsDigital-innovation and ultra-small dosage-form developmentAllRecognised in 2025 ministerial commendation
US sales operationProduction ceased 2025; Korea plant supplies US clientsUS brandsPlant sales: USD 14.25 m (first), second planned 2026

Cosmax Bio (HFF ODM)

OfferingDescriptionNotes
Tablets, softgels, liquids, powdersBroad dosage-form capabilityKorea and Shanghai
Jellies — "Jellix" lineDedicated jelly production line built Nov 2024; first stick-type jelly format in KoreaGrowth product
Individually-recognised ingredients5 MFDS approvals incl. perilla (차즈기) extractPer FY2025 annual-report summary
Export programsHalal and Australian TGA certifications; China >50% of exports; US, Vietnam, Indonesia, KazakhstanUSD 5 m export tower (Dec 2025)

Cosmax Pharma

Pharmaceutical intermediates and finished-drug manufacturing; product-level detail, pricing and flagship SKUs are not publicly disclosed in the sources reviewed.

Cosmax BTI (parent) services

OfferingDescription
Global raw-material purchasingGroup-level sourcing of cosmetic and HFF raw materials, resold to affiliates
Export agencyExport-agent services for subsidiaries
Shared services (SSC)Fees for finance, HR and other group services
New-business incubationCustom-cosmetics platform "3WAAU" (쓰리와우) for one-to-one personalised production (B2C pilot); marketing consulting (GrowX, reported 2026)

Cosmax, Inc. (equity-method associate) — key capabilities

CategoryDetail
SkincareCreams, serums, essences, sun care (sun care grew >50% in 2025 and reached ~10% of Korea sales in Q2 2025), gel masks
Color cosmeticsCushions, foundations, blushers, lip, eye — Shanghai strength
Hair/body, fragrance, baby care, herbal cosmetics, cosmeceuticalsFull-category ODM
ScaleKorea capacity ~780 m units (end-2024) expanding to ~1 bn units (end-2025)
Product-mix trendKorea skincare:color mix moved from 53:47 (Q1 2025) to 64:36 (Q1 2026)
Representative client brands (analyst-cited)Medicube, Anua, Equalberry, Dr. Althea, Numbuzin, Dr. Rejuall (SK Securities, April 2026)
Pricing modelPer-unit ODM contract pricing; specific pricing not publicly disclosed

Financial Narrative

Consolidated income statement

Sources: Revenue, operating income and FY2021–FY2024 net income from DART-based aggregator (Butler, FnGuide); FY2024–FY2025 gross profit and FY2025 net income (KRW 20.9 bn) from company Q4 2025 results summary (Quartr, March 2026). FY2021–FY2023 gross profit derived from published gross margins (16.0%, 14.3%, 17.5%). KRW 20.9 bn in company materials.

Revenue CAGR FY2021–FY2025: ≈2.9% p.a. (derived).

Attributable profit note (derived): FY2025 dividend of KRW 7.5 bn at a stated 25.5% payout implies consolidated profit attributable to owners of ≈KRW 29.4 bn, consistent with FnGuide FY2025 EPS of KRW 3,041. Attributable profit exceeds total net income because loss-making NBT (56% minority-owned) pushes losses onto non-controlling interests.

Quarterly trajectory: notes and sources

Sources: Cosmax BTI 1Q 2026 IR deck (quarterly chart, Q1'24–Q1'26); Q2 2026 derived from H1 2026 consolidated revenue KRW 444.1 bn and operating income KRW 32.6 bn (Seoul Times News, Oct 2026) minus Q1 2026.

H1 2026 vs H1 2025: notes and sources

Source: Seoul Times News (Oct 2026), DART-based. H1 2026 net income is inflated by the NBT tax refund (KRW 25.7 bn at NBT level) and higher equity-method income from Cosmax, Inc. (Q1 2026 equity-method income KRW 11.0 bn vs KRW 0.8 bn in Q1 2025).

Balance sheet

Sources: FY2024 — DART-based (Digital Today); FY2025 and Q1 2026 — Cosmax BTI 1Q 2026 IR deck. Discrepancy: a Q4 2025 summary (Quartr) reports FY2025 total assets of KRW 1,009.4 bn and equity of KRW 298.1 bn (vs. KRW 1,006.3 bn / 295.7 bn in the later IR deck — likely audit adjustments).

Cash & equivalents, total debt (short/long split), net debt, goodwill & intangibles: not publicly disclosed in the sources reviewed (the DART annual report would contain these; it was not directly accessible). Working capital (derived): FY2025 −KRW 278.2 bn; Q1 2026 −KRW 250.8 bn.

Cash flow

Operating cash flow, capex, free cash flow and buybacks for FY2021–FY2025: not publicly disclosed in sources reviewed. Dividends paid: FY2025 declared KRW 7.5 bn (paid 2026). No share buybacks identified; treasury shares (49,082) date from 2020.

Per-share data

Sources: FY2023 DPS KRW 350 (ETFshopping); FY2025 DPS KRW 780, +73.3% (Herald, CEO Score Daily, March 2026); FY2024 derived from the 73.3% increase. ETFshopping reports four consecutive annual dividend increases and a 5-year DPS CAGR of 25.6%. EPS: FY2025 KRW 3,041 (FnGuide, consolidated); TTM EPS KRW 6,641 (Judal, Oct 2026). Diluted EPS: not disclosed.

Commentary on trends, inflections and drivers

FY2021–FY2023: stagnation. Revenue rose only modestly from KRW 576.0 bn to KRW 628.6 bn as Korea's HFF market plateaued (KRW 6.15 tn in 2022 and 2023), NBT's US and Australian plants generated persistent losses (NBT US lost KRW 33.8 bn in 2022), and pharma remained in deficit. FY2022 was the trough: operating margin 0.6% and a net loss of KRW 20.2 bn.

FY2024: contraction. Revenue fell 4.9% to KRW 597.6 bn as domestic HFF demand softened (market −3.1% to KRW 5.95 tn) and Bio revenue fell ~10%. Gross margin nonetheless improved to 18.8% on mix and the faster-growing, higher-margin BTI-separate trading business.

FY2025: recovery begins. Revenue +8.0% to KRW 645.2 bn and operating profit +60.7% to KRW 27.0 bn, led by BTI-separate (+56.6%) riding Cosmax, Inc.'s record year, while NBT shrank (−9.5%) and booked a one-off US asset-disposal loss in Q3 2025 (Q3 consolidated net loss KRW 7.7 bn).

2026: inflection. Q1 2026 was the first quarter ever above KRW 200 bn revenue and KRW 10 bn operating profit; consolidated operating margin reached 8.0% (+3.8 pp YoY). H1 2026 operating profit doubled. Drivers: NBT's restructured footprint and China/Korea demand, Bio's recovery, and Cosmax, Inc.'s growth flowing through BTI-separate merchandise revenue, dividends and equity-method income.

Structural financial characteristics. (1) Thin consolidated margins (4–8%) relative to Cosmax, Inc. (8–9%); (2) a heavily current-weighted liability structure (86% of liabilities current at Q1 2026) implying short-term refinancing dependence; (3) liabilities at ~2.3x equity; (4) low interest coverage (~1.5x TTM). These are the principal financial vulnerabilities.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Structure

LayerEntityBTI stakeNotes

Apex

Cosmax BTI, Inc.

—

Controlled by Lee family (63.01% incl. related parties, June 2026)

Associate

Cosmax, Inc.

27.23% (27.51% incl. related)

~34 consolidated subsidiaries (China, US, Indonesia, Thailand, Italy, Japan etc.)

Subsidiary

Cosmax NBT

43.53%

Korea, Australia, China, US entities

Subsidiary

Cosmax Bio

68.37%

Korea, China (Shanghai)

Subsidiary

Cosmax Pharma

79.64%

Korea

Subsidiary (reported)

GrowX (그로우엑스)

——

Segment revenue (KRW Bn)

Segment revenue (KRW Bn)Q1 2024Q2 2024Q1 2025Q1 2026

NBT (consolidated)

71.080.972.293.3

BIO (consolidated)

35.644.637.447.9

PHARMA

10.88.38.58.6

BTI separate (holding)

28.429.846.271.9

Consolidated revenue

140.2159.0154.3205.2

Segment net income (KRW Bn)

Segment net income (KRW Bn)Q1 2024Q2 2024Q1 2025Q1 2026

NBT

-6.4-0.5-2.39.1

BIO

-1.9-0.3-1.01.3

PHARMA

-2.3-2.6-1.5-1.7

BTI separate

3.22.17.911.4

Annual revenue (KRW Bn)

Annual revenue (KRW Bn)FY2024FY2025

Cosmax NBT (consolidated)

317.6287.4

Cosmax Bio

146.7168.2

BTI separate

113.5177.7

Cosmax BTI consolidated

597.6645.2

Results by Segment

Cosmax NBT (KRW Bn)FY2023FY2024FY2025

Operating income

12.09.94.0

Net income

-5.8-5.4-15.1

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

576.0617.4628.6597.6645.2

Gross profit (KRW Bn)

92.288.3110.0112.3135.5

Operating income (KRW Bn)

11.93.420.216.827.0

Net income (KRW Bn)

4.3-20.22.58.020.9

Gross margin (%)

16.014.317.518.821.0

Operating margin (%)

2.10.63.22.84.2

Net margin (%)

0.7-3.30.41.33.2

Revenue growth YoY (%)

0.07.21.8-4.98.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (KRW Bn)

140.2159.0151.9146.5154.3163.7153.5173.7205.2238.9

Operating income (KRW Bn)

2.26.93.34.46.59.93.27.416.416.2

Income Statement and Margin Analysis (%) (Half-Yearly)

MetricH1 2025H1 2026

Revenue (KRW Bn)

318.0444.1

Operating income (KRW Bn)

16.432.6

Net income (KRW Bn)

5.865.7

Operating margin (%)

5.27.3

Financial Analysis

Line itemQ1 2025Q1 2026

Revenue

154.3205.2

Cost of sales

122.6158.9

Gross profit

31.746.3

SG&A

25.229.9

Operating income

6.516.4

Non-operating income/expense

-5.8-2.7

Equity-method income

0.811.0

Pre-tax income

1.524.7

Net income

-1.419.2

Net income attributable to owners

0.714.1

Balance Sheet and Margin Analysis (%)

MetricFY2024FY2025Q1 2026

Total assets (KRW Bn)

953.91,006.31,050.1

Total liabilities (KRW Bn)

672.7710.6733.9

Total equity (KRW Bn)

281.2295.7316.2

Liabilities-to-equity (%)

239.2240.3232.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

Balance sheet detail (KRW Bn)FY2025Q1 2026

Current assets

349.9380.0

Non-current assets

656.4670.1

Current liabilities

628.1630.8

Non-current liabilities

82.5103.1

Share capital

4.84.8

Capital surplus

235.0235.4

Other capital

-97.8-89.3

Retained earnings

133.5140.6

Non-controlling interests

20.224.7

Per-share (KRW)

Per-share (KRW)FY2023FY2024FY2025

Dividend per share (KRW)

350450780

Financial Analysis — ROE

RatioValueBasis / source

ROE

11.1%

FY2025, FnGuide

ROE (TTM)

19.7%

Butler, Oct 2026

ROA

≈2.1%

FY2025 net income / average assets (derived)

ROIC

2.6%

MarketInOut TTM (Aug 2026)

Current ratio

0.56x (FY2025); 0.60x (Q1 2026)

Derived

Liabilities / equity

2.40x (FY2025); 2.32x (Q1 2026)

Derived

Debt / equity

1.75x

MarketInOut TTM (definition: financial debt)

Interest coverage

1.51x

MarketInOut TTM

EV / EBITDA

6.5x (MarketInOut); 10.2x (FnGuide)

Vendor definitions differ

EBITDA (TTM)

KRW 99.5 bn

MarketInOut, Aug 2026 — unaudited vendor calculation

NBT revenue by region (KRW Bn)

NBT revenue by region (KRW Bn)FY2024FY2025

Overseas (KRW Bn)

221.6181.7

Domestic (KRW Bn)

96.0105.7

Group Entities

EntityQ1 2026 revenue (KRW Bn)YoY growth (%)

NBT Korea

72.640.6

NBT Australia

19.582.1

NBT USA

3.5-37.5

Bio Korea

39.726.7

Bio China

4.839.9

Revenue by Region

Cosmax, Inc. region (KRW Bn)FY2024FY2025

Korea (separate)

1,357.71,526.4

China (consolidated East)

574.3632.7

Cosmax BTI share price (KRW)

Cosmax BTI share price (KRW)31 Mar 202028 Oct 20255 Nov 202527 Mar 20266 Oct 202614 Oct 2026

Closing price (KRW)

10,75014,84013,69016,19023,85022,850

Performance Details

PerformanceValue

~1-year (28 Oct 2025 → 14 Oct 2026)

≈+54% (derived)

Since 31 Mar 2020

≈+113% (derived)

52-week range

KRW 11,810 – 29,150

Beta (1-year)

0.41–0.58 (FnGuide, differing dates)

Valuation Multiples

MultipleCosmax BTICosmax, Inc.Source

P/E (TTM)

≈3.5x

≈19.8x

Judal

P/B

≈0.69x

≈5.3x

Judal

EV/EBITDA

6.5x–10.2x (vendor-dependent)

10.3x (2026E, Hanwha)

MarketInOut, FnGuide, Hanwha

EV/Sales

≈0.93x

—

MarketInOut

Dividend yield

≈3.4% (KRW 780 / KRW 22,850)

≈1.1% (KRW 3,300 / KRW 306,500)

Derived

Holding Details

HoldingShares held (approx.)Price (KRW)Value (KRW Bn)

Cosmax, Inc. (27.23%)

3.09 m

306,500 (9 Oct)

≈947

Cosmax NBT (43.53%)

8.98 m

5,080 (15 Oct)

≈46

Listed holdings total

——

≈993

Cosmax BTI market cap

9.60 m

22,850 (14 Oct)

≈219

Analyst Conclusions

Guidance and expectations

BTI: no numeric guidance; qualitative direction is continued HFF export growth, portfolio diversification and pharma product launches. H1 2026 run-rate (revenue KRW 444.1 bn, OP KRW 32.6 bn) implies FY2026 revenue plausibly above KRW 850 bn and OP above KRW 55 bn if H2 merely matches H1 — an illustrative extrapolation, not guidance.

NBT: DS Investment projects 2026 revenue KRW 374.6 bn (+30%).

Cosmax, Inc.: H1 2026 revenue KRW 1,476.9 bn (+22%) and OP KRW 126.8 bn (+13%); management expects US turnaround and skincare momentum to continue in H2.

Bull case

  1. Discount closure: with listed stakes worth ~4.5x market cap, modest discount narrowing (e.g., via higher payouts, value-up pressure, or simplification) offers large upside.

  2. HFF operating leverage: NBT's restructured cost base produced a 11% OPM in Q1 2026; sustained growth of 30% could make HFF a genuine second profit engine.

  3. Associate compounding: Cosmax, Inc.'s US profitability, Europe entry and L'Oréal partnership extend its growth runway, raising equity-method income and dividends to BTI.

Bear case

  1. Leverage and liquidity: liabilities 2.3x equity, current ratio 0.6x and ~1.5x interest coverage leave little margin for error if HFF demand falters.

  2. Earnings quality: 2026 profits are flattered by one-offs (KRW 25.7 bn tax refund) and equity-method income BTI cannot freely access; underlying HFF growth has historically proven cyclical.

  3. Governance overhang: controlling-family stake of 63%, succession via personal companies and an abrupt professional-CEO exit may keep minority-shareholder discounts structurally wide.

Catalysts and monitorables (next 12 months)

  • Q3 2026 results (expected mid-November 2026): NBT growth sustainability ex-tax refund; BTI-separate revenue.

  • FY2026 dividend decision (Q1 2027): payout and high-dividend status renewal.

  • Second NBT US plant sale and deleveraging.

  • Cause and resolution of NBT's ~55% share-price decline from its 52-week high.

  • Any group restructuring, merger or stake simplification following the May 2026 control transfer.

  • Execution of Keminova integration and first L'Oréal joint projects.

  • Korean holding-company/value-up regulatory developments.

Concluding analyst verdict

Cosmax BTI presents one of the clearest examples on the Korean market of a holding company whose share price detaches from the value of what it owns. At roughly KRW 219 bn, the market values BTI at about a fifth of the market value of its Cosmax, Inc. and Cosmax NBT stakes alone, while ignoring unlisted Cosmax Bio and Pharma. The discount is not irrational, but it is extreme. It reflects real issues: a consolidated balance sheet carrying liabilities more than twice equity with most of them current, interest coverage near 1.5x, a decade of disappointing HFF returns, missed targets at Cosmax Bio, and a governance model in which the founding family controls about 63% and has used personal companies to engineer succession.

What has changed in 2026 is the operating evidence. For the first time the consolidated business is compounding at scale — Q1 revenue +33%, H1 operating profit roughly doubled — and the improvement is rooted in structural action (exiting US HFF manufacturing) and exogenous tailwinds (K-beauty and K-wellness exports, China recovery) rather than accounting alone, although H1 net income is inflated by a one-off tax refund. Meanwhile the associate, Cosmax, Inc., has delivered record quarters, a first US profit, a European foothold and a high-profile L'Oréal partnership.

The investment debate therefore reduces to governance and capital allocation rather than operations. If the newly consolidated family leadership under Lee Byung-joo (holding) and Lee Byung-man (cosmetics) uses the earnings upswing to deleverage, raise payouts further and simplify the structure, the discount could narrow materially. If the holding structure continues to serve primarily as a control and succession vehicle, the stock may remain a perennially "cheap" proxy.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundAge / born

Lee Kyung-soo

Founder; Chairman, Cosmax BTI

Founded group 1992; transferred all personal BTI shares to sons by 2023

Born 1946

Suh Sung-suk

Co-founder; Chairwoman (Group HR)

Largest shareholder until May 2026; now 13.83%

Born 1952

Lee Byung-joo

Vice Chairman & sole CEO, Cosmax BTI (since 10 Sep 2026)

Joined group 20+ years ago; roles in talent development, management support; headed Cosmax NBT USA and Cosmax USA; Cosmax, Inc. CEO 2023–Mar 2025

Born 1979

Lee Byung-man

Vice Chairman & CEO, Cosmax, Inc.; largest BTI shareholder

Joined Cosmax 2005; led overseas marketing at BTI from 2016; Cosmax CEO 2020–2023 and again from Mar 2025; BTI CEO 2023–2025; MBA, Shanghai Jiao Tong University

Born 1978

Huh Min-ho

Former Senior Vice Chairman & co-CEO, Cosmax BTI

Ex-CEO of CJ Olive Young and CJ ENM Commerce; joined Mar 2025; resigned 10 Sep 2026 citing personal reasons

Age 62 (2026)

Choi Kyung

Vice Chairman & co-CEO, Cosmax, Inc.

Signed L'Oréal MOU (Sep 2026)

—

Kim Nam-joong

CEO, Cosmax NBT

Received ministerial commendation (Dec 2025)

—

Kim Yong-beom

Head of Group Planning & Management, Cosmax BTI

Inside director of SSY

—

Shin Yoon-seo

Head of Group Finance, Cosmax BTI

Inside director of BJH

—

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

Mar 2023

Lee Byung-man and Lee Byung-joo appointed BTI co-CEOs

Replaced professional managers

27 Mar 2025

Lee Byung-man moves to Cosmax, Inc. CEO; Lee Byung-joo to BTI; Huh Min-ho joins as BTI co-CEO

Brother role swap; professional retail executive added

Late 2025

Brothers promoted to Vice Chairman; Huh to Senior Vice Chairman

Generational transition

10 Sep 2026

Huh resigns; Lee Byung-joo sole CEO

Company says no business issue involved

Major Shareholders

ShareholderStakeDate / source

Lee Byung-man (largest shareholder)

19.95% direct

June 2026 (Asia Today)

Suh Sung-suk

13.83%

June 2026

Lee Byung-joo

10.52%

June 2026

Cos M&M (family-owned company)

9.43%2025

SSY Co. (100% Lee Byung-man)

≈4.39% (421,670 shares)

May 2026

BJH Co. (100% Lee Byung-joo)

≈4.39% (421,670 shares)

May 2026

Largest shareholder + related parties

63.01%

June 2026

Unnamed 5%+ holder

5.59% (537,179 shares)

—

Treasury shares

0.51%—

Minority shareholders (4,019 holders)

32.7%

FY2025 annual report

Competitive Landscape

Peer Comparison FY2025

CompanyRevenueRevenue growth YoYOperating marginR&D intensity

Cosmax BTI (consolidated)

KRW 645.2 bn

+8.0%4.2%—

Cosmax, Inc. (associate)

KRW 2,398.8 bn

+10.7%8.2%

5.54% (2026)

Kolmar Korea

KRW 2,722.4 bn

—8.8%—

Novarex

KRW 404.3 bn

+36%10.7%—

Intercos

≈€1.05 bn

≈0% to −1.7% (sources differ)

Adj. EBITDA margin 14.9%

—

“—” = not publicly disclosed.

Company Snapshot

$454M

Revenue

341

Employees

1992

Founded

Seongnam, South Korea

Headquarters

SWOT Analysis

Strengths

  • Control of the world's largest cosmetics ODM: 27.23% of Cosmax, Inc., which posted FY2025 revenue KRW 2,398.8 bn and record Q2 2026 OP KRW 73.7 bn.
  • Look-through value far above market cap: BTI's Cosmax, Inc. stake (≈3.09 m shares) was worth ≈KRW 947 bn at KRW 306,500 (9 Oct 2026) vs. BTI market cap ≈KRW 219 bn (derived).
  • HFF turnaround evidenced: NBT Q1 2026 OP KRW 10.3 bn (+1,080%) and Q2 revenue KRW 102.3 bn (+35.2%).
  • Global HFF footprint: NBT overseas revenue share >70%; USD 70 m export tower (Dec 2025).
  • Improving shareholder returns: DPS up from KRW 350 (FY2023) to KRW 780 (FY2025); high-dividend company status.
  • Strategic validation: L'Oréal MOU (Sep 2026) and 20+-year L'Oréal relationship.

Weaknesses

  • Thin consolidated margins: FY2025 OPM 4.2%; FY2022 0.6%.
  • Balance-sheet strain: liabilities 2.32x equity and current ratio 0.60x at Q1 2026; TTM interest coverage ~1.5x.
  • Chronic losses in parts of the portfolio: Cosmax Pharma loss-making each quarter reviewed; NBT net losses FY2023–FY2025.
  • Missed targets: Cosmax Bio's KRW 500 bn-by-2026 goal vs KRW 168.2 bn FY2025 revenue.
  • Earnings quality: H1 2026 net income lifted by a one-off KRW 25.7 bn NBT tax refund and equity-method gains.
  • Limited disclosure: no published consolidated cash-flow, debt maturity or geographic splits in readily accessible IR materials.

Opportunities

  • Holding-discount narrowing via Korean "value-up" policy and higher payouts.
  • K-wellness exports — industry target of KRW 5 tn HFF exports by 2035.
  • Associate expansion: Europe via Keminova; US profitability since Q2 2026.
  • Product innovation with L'Oréal across ingredients and sensory formats.
  • China recovery: Bio China +39.9% and NBT China-bound demand in Q1 2026.
  • Asset monetisation: second NBT US plant sale to deleverage.

Threats

  • Domestic HFF stagnation: market KRW 5.96 tn in 2025 vs KRW 6.15 tn in 2022.
  • Customer concentration at associate: Cosmax, Inc. Korea top-10 clients ≈50% of sales (Q1 2025).
  • Margin pressure: Cosmax, Inc. Q3 2025 OP −1.6% despite +10.5% revenue; Q1 2026 OP growth only 3%.
  • Tariffs and trade: US customs volatility cited by global peers.
  • Governance/succession risk: sudden exit of professional co-CEO after 18 months; family-company share transfers.
  • Subsidiary share volatility: NBT shares down >50% from 52-week high by mid-Oct 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
25 Mar–17 Apr 2025Suh Sung-suk buys 90,600 BTI shares; stake to 21.62%First purchase since Aug 2022; "responsible management"
14 May 2025Q1 2025 results: revenue KRW 154.3 bn, OP KRW 6.5 bn, net loss KRW 1.4 bnWeak start
14 Aug 2025H1 2025 report: Q2 revenue KRW 163.7 bn, OP KRW 9.9 bnGradual improvement
1 Sep 2025Multiple filings incl. M&A-category and subsidiary-loan filings–
21 Oct–3 Nov 2025Suh buys further shares; stake to 22.61%Pre-succession consolidation
29 Oct 2025Cosmax, Inc. madecassoside-exosome patentIP
Nov 2025Q3 2025: revenue KRW 153.5 bn, OP KRW 3.2 bn, net loss KRW 7.7 bn (NBT US asset disposal)Restructuring charge
Nov 2025Cosmax, Inc. corporate value-up plan publishedGovernance/returns
4 Dec 2025NBT USD 70 m export tower; Bio USD 5 m export towerExport momentum
10 Dec 2025Cosmax, Inc. EcoVadis Gold, 2nd year, top 2%ESG
16 Dec 2025Dividend-amount notices filedShareholder returns
Late 2025Lee brothers promoted to Vice ChairmanSuccession
23 Feb 2026Cosmax, Inc. FY2025 record results; Keminova 51% SPAAssociate growth; Europe entry
Feb 2026BTI FY2025: revenue KRW 645.2 bn (+8.0%), OP KRW 27.0 bn (+60.7%)Recovery
Feb 2026NBT minority shareholders seek inspection of accounting booksGovernance pressure at subsidiary
17 Mar 2026FY2025 annual report filedFiling
23 Mar 2026SSY and BJH incorporated (KRW 10 bn capital each)Succession vehicles
26 Mar 2026High-dividend company designation; DPS KRW 780 (+73.3%)Tax-advantaged dividends
3 Apr 2026Suh files plan to sell 10.29% to SSY/BJHSuccession signal
Apr 2026Keminova acquisition closedEurope
7–8 May 2026NBT record Q1 (revenue KRW 93.3 bn, OP KRW 10.3 bn); BTI shares up >20% intradayRe-rating catalyst
14 May 2026BTI Q1 2026: revenue KRW 205.2 bn (+33.0%), OP KRW 16.4 bn (+150.9%)Record quarter
May 2026Largest shareholder changes to Lee Byung-man (8.78% transferred)Control transition
7 Aug 2026NBT Q2: revenue KRW 102.3 bn, OP KRW 8.5 bn, net income KRW 30.3 bn (incl. KRW 25.7 bn tax refund)First KRW 100 bn quarter
11 Aug 2026Cosmax, Inc. Q2 record: revenue KRW 794.9 bn, OP KRW 73.7 bn; US first quarterly profitAssociate inflection
Aug 2026BTI H1 2026: revenue KRW 444.1 bn (+39.6%), OP KRW 32.6 bn (+98.7%), net income KRW 65.7 bnEarnings step-up
1 Sep 2026Loan decision (subsidiary major matter) filedIntra-group funding
8–9 Sep 2026L'Oréal–Cosmax MOUStrategic validation
10 Sep 2026Huh Min-ho resigns; Lee Byung-joo sole CEO; large-holding report filedGovernance
16 Sep 2026Large-holding status report (general) filedOwnership
Sep–Oct 2026NBT shares fall from KRW 11,200 52-week high to ~KRW 5,080 (15 Oct)–
1 Oct 2026Subsidiary-incorporation filing (reportedly GrowX)New business
14 Oct 2026BTI closes at KRW 22,850~+54% vs Oct 2025

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment: NBT (consolidated) rose from KRW 71 Bn in Q1 2024 to KRW 93.3 Bn in Q1 2026.
Cosmax BTI, Inc. — Revenue by Segment
Series (KRW Bn)Q1 2024Q2 2024Q1 2025Q1 2026
NBT (consolidated)7180.972.293.3
BIO (consolidated)35.644.637.447.9
PHARMA10.88.38.58.6
BTI separate (holding)28.429.846.271.9
Consolidated revenue140.2159154.3205.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.